Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mirvetuximab soravtansine - ImmunoGen

Next Previous
Drug Profile

Mirvetuximab soravtansine - ImmunoGen

Alternative Names: Anti-FOLR1-monoclonal-antibody-maytansinoid-conjugate-IMGN-853; ELAHERE; IMGN-853; M9346A-sSPDB-DM4; M9346A-sulfo-SPDB-DM4; MIRV; Mirvetuximab soravtansine-gynx; TAK-853

Latest Information Update: 06 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoGen
  • Developer Hangzhou Zhongmei Huadong Pharmaceutical; ImmunoGen; Takeda
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Endometrial cancer; Triple negative breast cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 29 Sep 2025 AbbVie plans to launch Mirvetuximab soravtansine in the UK
  • 20 Aug 2025 AbbVie plans a phase II trial for Ovarian cancer, Fallopian tube cancer and Peritoneal cancer (Late-stage disease, Combination therapy) in USA (IV) (NCT06890338)
  • 24 Jul 2025 Registered for Fallopian tube cancer (Second-line therapy or greater, Late-stage disease) in United Kingdom (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top